Lv1
64 积分 2025-01-09 加入
Nanozyme‐Mediated PROTACs Delivery for Targeted Protein Degradation and Ferroptosis Sensitization in Prostate Cancer
3小时前
待确认
GOT2 Silencing Promotes Reprogramming of Glutamine Metabolism and Sensitizes Hepatocellular Carcinoma to Glutaminase Inhibitors
2个月前
已完结
Ensemble fuzzy models in personalized medicine: Application to vasopressors administration
4个月前
已完结
Rucaparib for metastatic castration-resistant prostate cancer (mCRPC): TRITON3 interim overall survival and efficacy of rucaparib vs docetaxel or second-generation androgen pathway inhibitor therapy
4个月前
已完结
In Silico-Driven THIOMAB Approach for Stable PROTAC Conjugates by Docking Payloads in Antibody Cavities
5个月前
已完结
Coronado CLL: A Phase Ib/II Trial of Combination Rp-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refract ory Chronic Lymphocytic Leukemia
5个月前
已关闭
Coronado CLL: A Phase Ib/II Trial of Combination Rp-3500 and Olaparib in DNA Damage Repair Pathway Deficient Relapsed/Refract ory Chronic Lymphocytic Leukemia
5个月前
已关闭
Multi-drug delivery nanocarriers for combination therapy
7个月前
已完结
Advancements in nanotechnology for PARP inhibitor delivery: a comprehensive review of diverse nanosystems, their mechanisms, and therapeutic applications across cancer and beyond
10个月前
已完结
Paclitaxel sensitizes homologous recombination-proficient ovarian cancer cells to PARP inhibitor via the CDK1/BRCA1 pathway
10个月前
已完结
皖公网安备34019202002308
